Research
Hormonal
Semaglutide has a favorable cardiovascular safety profile, with cardiovascular outcome trials (SUSTAIN-6, PIONEER-6) showing no increased risk of major adverse cardiovascular events (MACE) compared to placebo.
Semaglutide is safe for your heart. Large studies have shown it does not increase the risk of heart attack, stroke, or cardiovascular death in people with type 2 diabetes, and may even offer benefits.
StrongSupportsVERY_HIGH confidence
SUSTAIN-6 is the cardiovascular outcome trial (CVOT) of subcutaneous semaglutide... PIONEER 6, was the CVOT... Given the beneficial metabolic and cardiovascular actions of semaglutide... semaglutide has an overall favorable risk/benefit profile
Why this rating
Based on large, event-driven cardiovascular outcome trials (CVOTs).
Source
Safety of Semaglutide
Mark M. Smits et al. · Frontiers in Endocrinology · 2021
DOI 10.3389/fendo.2021.645563
narrative_review · n=21500Cited 267×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (both oral and subcutaneous formulations) is associated with a high incidence of mild-to-moderate, transient gastrointestinal adverse effects (nausea, vomiting, diarrhea), which are dose-dependent and time-dependent, occurring primarily during the initial 8-12 weeks of treatment.Strong
- Semaglutide does not significantly increase the risk of hypoglycemia in patients not using concomitant insulin or sulfonylureas, due to its glucose-dependent mechanism of action.Strong
- Semaglutide increases the risk of biliary disease (cholelithiasis), which is a class effect of GLP-1 receptor agonists, likely due to rapid weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →